| Phase 3 CRUISE-1 trial to treat iron deficiency anemia in dialysis patients begins - NephrOnline |
|
|
NephrOnline Renal biopharmaceutical company Rockwell Medical announced that it has started enrollment in its Phase 3 CRUISE-1 clinical study of Soluble Ferric Pyrophosphate (SFP), designed to treat iron deficiency anemia in hemodialysis patients receiving ... Rockwell Medical Starts Pivotal Phase III Clinical Study for Treatment of Iron |